Gen1E Lifesciences Inc
GEn1E Lifesciences Inc, based in Palo Alto, California, is a clinical-stage company focused on accelerating first-in-class precision therapies for inflammatory rare diseases. With a robust pipeline featuring three key programs, the company has progressed from Early Discovery to Phase 2 in just 2.5 years, utilizing novel therapies that target kinase dysregulation effectively.
The company's innovative GRID AI platform leverages a rich database and machine learning models to streamline drug discovery and development, aiming to address significant unmet medical needs. GEn1E's differentiated approach to developing selective dual signal modifiers offers a promising alternative to traditional kinase inhibitors, minimizing immunosuppressive effects and enhancing therapeutic specificity.
Generated from the website
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.